What is Retatrutide?Overview
Retatrutide is an investigational weight loss medication from Eli Lilly that represents a breakthrough in obesity pharmacotherapy. As a triple hormone receptor agonist (GIP + GLP-1 + glucagon), it achieved 24.2% weight loss in Phase 2 trials—the highest ever reported for a single-agent obesity medication.[1]
- Triple Mechanism: First weight loss drug to activate GIP, GLP-1, AND glucagon receptors—providing appetite suppression PLUS increased energy expenditure and fat burning.
- Record-Breaking Results: Phase 2 trial: 24.2% weight loss at 48 weeks[1] (highest dose, 12 mg weekly). 37% of participants lost ≥25% of body weight, and 17% lost ≥30%.
- Current Status: Phase 3 TRIUMPH trials ongoing. NOT FDA-approved—only available through clinical trials. Expected FDA filing: late 2025/Q1 2026.
Explore Phase 2 and TRIUMPH trial results in detail
FDA Status & TimelineTrack approval status and regulatory milestones
Insurance Coverage GuideCoverage predictions by plan type when approved
Side Effects & SafetyCommon side effects and management strategies
Retatrutide vs TirzepatideHead-to-head comparison: triple vs dual agonist
Injectable Administration
Retatrutide is a once-weekly subcutaneous injection (shot under the skin), similar to semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).[9] The injection is self-administered using a pre-filled pen device.
Note: Retatrutide is NOT an oral medication. It is a weekly injection like other GLP-1 receptor agonists.
How Retatrutide WorksMechanism Overview
Retatrutide is the only weight loss medication to activate three hormone receptors simultaneously: GIP, GLP-1, and glucagon. This triple mechanism provides complementary effects that work together to maximize weight loss.[1][10]
- Enhances insulin secretion after meals
- Reduces food intake
- May improve fat metabolism
- Increases satiety (feeling full)
- Slows stomach emptying[11]
- Reduces appetite
- Improves blood sugar control
This is what makes retatrutide different:
- Increases energy expenditure (fat burning)
- Promotes fat breakdown
- May prevent metabolic slowdown during weight loss
- Only weight loss drug to activate glucagon receptor
Why This Matters: Current GLP-1 medications (semaglutide, tirzepatide) work primarily by reducing appetite. Retatrutide adds a second pathway—increasing energy expenditure through glucagon activation—which may explain its superior weight loss results.
Who Might Prefer Retatrutide?
Retatrutide may be ideal for patients who:
- Need maximum weight loss – Seeking the most effective obesity medication available
- Plateaued on other GLP-1s – Lost weight with semaglutide or tirzepatide but want more
- Have severe obesity – BMI ≥35 with significant weight-related health complications
- Can tolerate injections – Comfortable with once-weekly subcutaneous injection
- Have type 2 diabetes + obesity – Need aggressive management of both conditions
Clinical EvidenceTrial Results
Phase 2 Obesity Trial (NEJM, June 2023)[9]
Primary Results:[1]
- Mean weight loss: 24.2% at 12 mg dose (48 weeks)
- 22.8% at 8 mg dose
- 17.1% at 4 mg dose
- Placebo: 2.1%
Responder Analysis:
- 37% of participants lost ≥25% of body weight (12 mg dose)
- 17% lost ≥30% of body weight
- Also improved blood pressure, waist circumference, and metabolic markers
Phase 3 TRIUMPH Trials (Ongoing)
TRIUMPH Trial Program:
- TRIUMPH-1: Obesity (N=2,300) – Results expected 2025-2026[7]
- TRIUMPH-2: Type 2 Diabetes + Obesity (N=1,000) – Results expected 2025-2026[8]
- TRIUMPH-3: Obesity + Cardiovascular Disease (N=1,800) – Results expected 2025-2026[5]
- TRIUMPH-4: Obesity + Osteoarthritis – Results expected 2025[2]
All GLP-1 Medications Comparison
Safety and Side EffectsSafety Profile
Phase 2 trials show retatrutide's safety profile is consistent with the GLP-1 class. The most common side effects are gastrointestinal and primarily occur during dose escalation.[1]
Most Common Side Effects
- Nausea: 14-60% (dose-dependent)
- Diarrhea
- Vomiting
- Constipation
Characteristics:
- Primarily occur during dose escalation
- Mostly mild to moderate severity
- Transient (improve over time)
- Can be mitigated with lower starting dose (2mg vs 4mg)
Discontinuation rate: 6-16% (dose-dependent)
Serious adverse events: Rare (1 case of pancreatitis in Phase 2)
- Severe abdominal pain or persistent vomiting – may indicate pancreatitis
- Vision changes or blurred vision – can indicate diabetic retinopathy
- Rapid heartbeat or palpitations – especially with dizziness
- Thyroid tumor symptoms – neck lump, hoarseness, trouble swallowing or breathing
- Allergic reaction – rash, swelling (face/tongue/throat), severe dizziness, breathing difficulty
- Severe nausea – preventing eating/drinking for 24+ hours
- Gallbladder problems – jaundice, fever with stomach pain, clay-colored stools
Path to FDA ApprovalApproval Timeline
Expected Filing and Approval Timeline
Current Status: Phase 3 TRIUMPH trials ongoing (results expected 2025-2026).
Projected NDA Submission: Late 2025 - Q1 2026 (speculative—no official announcement).
Projected FDA Approval: Late 2026 - Mid 2027 (highly speculative).
Commercial Launch: 2027 (highly speculative).
Important: These timelines are projections based on typical drug development timelines. Actual approval dates depend on Phase 3 trial results, FDA filing timing, and regulatory review speed. Eli Lilly has not announced official timelines.
Current AccessClinical Trials
While retatrutide awaits FDA approval, you can access it now through clinical trial enrollment:
- Free medication – No cost for retatrutide or placebo
- Free medical monitoring – Regular check-ups, lab tests, physician visits at no charge
- No insurance required – Trials cover all study-related costs
- Possible compensation – Some trials pay for time and travel expenses
- Early access – Get retatrutide before FDA approval (projected 2026-2027)
How to Enroll in Retatrutide Trials
Enrolling in a retatrutide clinical trial typically follows these steps:
- Find active trials: Search ClinicalTrials.gov for "retatrutide"
- Contact the site: Call or submit an online inquiry to express interest
- Complete screening: Phone interview to verify basic eligibility criteria
- In-person visit: Medical exam, lab tests, and detailed eligibility assessment
- Sign consent: Review and sign informed consent documents if eligible
- Begin treatment: Start receiving retatrutide or placebo per study protocol
Am I Eligible? Trial Criteria
Common inclusion criteria for retatrutide trials:
- For obesity trials: BMI ≥30 (or ≥27 with weight-related conditions)
- For type 2 diabetes trials: A1C ≥7.0%, BMI ≥25
- Age requirements: Typically 18-75 years old
Common exclusion criteria:
- History of pancreatitis or pancreatic disease
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- Severe kidney or liver disease
- Recent cardiovascular events (within 3-6 months)
- Pregnancy, breastfeeding, or planning to become pregnant
Find Trials Near You
To find retatrutide clinical trials in your area:
- ClinicalTrials.gov – Filter by location, distance, and recruiting status
- TRIUMPH-1: NCT05929066
- TRIUMPH-2: NCT05929079
- TRIUMPH-3: NCT05882045
Get trial updates and enrollment opportunities
Insurance Coverage OutlookCoverage Outlook
Post-Approval Coverage Predictions
Current Status: Retatrutide is NOT FDA-approved. No insurance coverage available.
Expected Coverage by Plan Type (Post-Approval):
- Commercial Insurance: Limited initial coverage with prior authorization requirements. Step therapy likely (try cheaper options first). Gradual expansion 6-12 months post-approval.
- Medicare Part D: By law, basic Part D coverage excludes drugs used for weight loss, and retatrutide is not a Medicare GLP-1 Bridge drug. May cover for type 2 diabetes indication.
- Medicaid: Highly variable by state. Some states provide broad coverage, others very restrictive.
Expected Cost Without Insurance: $1,000-1,500/month (projection based on similar GLP-1 medications).[6]
See complete coverage guide with appeals strategiesFAQs
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), while tirzepatide is a dual agonist (GIP + GLP-1 only). The addition of glucagon receptor activation increases energy expenditure and fat burning, which may explain the higher efficacy.[1][10] Retatrutide also delays gastric emptying more effectively than selective GLP-1 agonists.[11]
Injectable. Retatrutide is a once-weekly subcutaneous injection (shot under the skin), just like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).[9]
Projected approval: late 2026 to mid 2027. This is speculative—actual timing depends on Phase 3 trial results (2025-2026[2]), NDA filing (projected late 2025/Q1 2026), and FDA review (6-12 months). No official timeline has been announced by Eli Lilly.
Unknown until FDA approval. If approved, expect: (1) Limited initial coverage with prior authorization requirements, (2) Step therapy (try cheaper options first), (3) Gradual expansion 6-12 months post-approval. Cost without insurance likely $1,000-1,500/month.[6]
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- CNBC. Eli Lilly to release weight loss drug retatrutide data in 2025. February 6, 2025. https://www.cnbc.com/2025/02/06/eli-lilly-to-release-weight-loss-drug-retatrutide-data-in-2025.html (TRIUMPH-4 acceleration announcement)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PubMed
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). NCT05882045. https://clinicaltrials.gov/study/NCT05882045
- NBC News. As costs of weight loss drugs like Wegovy and Zepbound go down, how low can prices go? January 9, 2025. https://www.nbcnews.com/health/health-news/cost-weight-loss-drugs-wegovy-zepbound-how-low-prices-down-rcna205911
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity (TRIUMPH-1). NCT05929066. https://clinicaltrials.gov/study/NCT05929066
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes and Obesity (TRIUMPH-2). NCT05929079. https://clinicaltrials.gov/study/NCT05929079
- ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. NCT04881760. https://clinicaltrials.gov/study/NCT04881760
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X. PubMed
- Urva S, O'Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. doi:10.1111/dom.15167. PubMed
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.